drugset / Trial / NCT05137314
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
Phase 1
Completed
14 enrolled
Peptilogics
Biomedical Advanced Research and Development Authority · collabWellcome Trust · collab
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .
Timeline
- Start
- 2022-03-31
- Primary completion
- 2024-03-19
- Completion
- 2024-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PLG0206 | Peptide | 3 mg/ml | Other |
| Subject | PLG0206 | Peptide | 10 mg/ml | Other |